[{"id":"52201742-0575-4575-a34b-9248823aad77","acronym":"APAL2020SC","url":"https://clinicaltrials.gov/study/NCT04726241","created_at":"2021-01-27T13:53:55.563Z","updated_at":"2025-02-25T15:11:53.004Z","phase":"Phase 1/2","brief_title":"The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia \u0026 Lymphoma Society and Children's Oncology Group Study","source_id_and_acronym":"NCT04726241 - APAL2020SC","lead_sponsor":"LLS PedAL Initiative, LLC","biomarkers":" KMT2A","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"],"overall_status":"Recruiting","enrollment":" Enrollment 960","initiation":"Initiation: 04/18/2022","start_date":" 04/18/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-13"},{"id":"f1031737-80a9-4c8b-a2a6-14dc6ec95216","acronym":"SL03-OHD-104","url":"https://clinicaltrials.gov/study/NCT05275439","created_at":"2022-03-11T15:53:40.765Z","updated_at":"2025-02-25T15:44:45.150Z","phase":"Phase 1","brief_title":"Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML","source_id_and_acronym":"NCT05275439 - SL03-OHD-104","lead_sponsor":"Shattuck Labs, Inc.","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • SL-172154"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 03/17/2022","start_date":" 03/17/2022","primary_txt":" Primary completion: 02/06/2025","primary_completion_date":" 02/06/2025","study_txt":" Completion: 02/06/2025","study_completion_date":" 02/06/2025","last_update_posted":"2025-02-11"},{"id":"0d9ce0fd-f1c5-49a0-8195-840b50eca958","acronym":"MT2015-29","url":"https://clinicaltrials.gov/study/NCT03314974","created_at":"2021-01-18T16:22:16.872Z","updated_at":"2025-02-25T16:52:01.168Z","phase":"Phase 2","brief_title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","source_id_and_acronym":"NCT03314974 - MT2015-29","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2026","study_completion_date":" 06/10/2026","last_update_posted":"2025-02-04"},{"id":"d849c811-e1a4-4e2a-879f-f191f73d4644","acronym":"TCD17197","url":"https://clinicaltrials.gov/study/NCT05086315","created_at":"2023-08-14T10:11:07.011Z","updated_at":"2024-07-02T16:35:00.248Z","phase":"Phase 1/2","brief_title":"First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","source_id_and_acronym":"NCT05086315 - TCD17197","lead_sponsor":"Sanofi","biomarkers":" IL3RA","pipe":"","alterations":" ","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bexatamig (IPH6101)"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 12/08/2021","start_date":" 12/08/2021","primary_txt":" Primary completion: 12/11/2025","primary_completion_date":" 12/11/2025","study_txt":" Completion: 11/11/2026","study_completion_date":" 11/11/2026","last_update_posted":"2024-05-29"},{"id":"02eaf617-0513-44fc-bea7-b3c0c01ecd8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05849662","created_at":"2023-05-09T14:04:18.433Z","updated_at":"2024-07-02T16:35:02.520Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia","source_id_and_acronym":"NCT05849662","lead_sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","biomarkers":" KRAS • NRAS • NF1 • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation","tags":["KRAS • NRAS • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • cytarabine • azacitidine • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 05/10/2024","start_date":" 05/10/2024","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-05-20"},{"id":"7228addd-99a0-4c5e-a6f3-befe14f6f6de","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800210","created_at":"2023-04-05T14:03:37.666Z","updated_at":"2024-07-02T16:35:05.164Z","phase":"Phase 2","brief_title":"Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases","source_id_and_acronym":"NCT05800210","lead_sponsor":"University of Florida","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • CBL mutation • Chr t(9;11)","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • CBL mutation • Chr t(9;11)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/03/2024","start_date":" 05/03/2024","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-05-08"},{"id":"7ec7759c-7cb8-4dd1-b937-cc10b7eb5153","acronym":"","url":"https://clinicaltrials.gov/study/NCT04640987","created_at":"2021-01-29T07:21:37.582Z","updated_at":"2024-07-02T16:35:08.606Z","phase":"Phase 1","brief_title":"Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback","source_id_and_acronym":"NCT04640987","lead_sponsor":"Porteus, Matthew, MD","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 01/20/2020","start_date":" 01/20/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-04-19"},{"id":"b90d0390-a592-4a17-be55-4a843bf4b331","acronym":"","url":"https://clinicaltrials.gov/study/NCT03326921","created_at":"2021-01-29T07:15:51.429Z","updated_at":"2024-07-02T16:35:13.551Z","phase":"Phase 1","brief_title":"HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant","source_id_and_acronym":"NCT03326921","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-A • CD4","pipe":" | ","alterations":" HLA-A*02:01","tags":["HLA-A • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • HA-1 T TCR T Cell Immunotherapy"],"overall_status":"Suspended","enrollment":" Enrollment 24","initiation":"Initiation: 02/23/2018","start_date":" 02/23/2018","primary_txt":" Primary completion: 10/16/2027","primary_completion_date":" 10/16/2027","study_txt":" Completion: 07/16/2028","study_completion_date":" 07/16/2028","last_update_posted":"2024-03-21"},{"id":"be1b1cbc-6baf-4848-9f92-082e2b4cd6b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01203722","created_at":"2021-01-18T04:49:23.205Z","updated_at":"2024-07-02T16:35:15.050Z","phase":"Phase 1/2","brief_title":"Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies","source_id_and_acronym":"NCT01203722","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" FLT3 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • MLL rearrangement • MLL rearrangement • Chr t(9;11)","tags":["FLT3 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • MLL rearrangement • MLL rearrangement • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-13"},{"id":"8a9ebf00-3ead-4be6-b6da-08e24836e50c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05011422","created_at":"2021-08-18T14:53:38.899Z","updated_at":"2024-07-02T16:35:15.459Z","phase":"Phase 1","brief_title":"Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies","source_id_and_acronym":"NCT05011422","lead_sponsor":"Washington University School of Medicine","biomarkers":" FLT3 • NPM1 • RUNX1 • KMT2A • ETV6 • CD38 • CREBBP • NUP98 • AFF1 • HLA-DRB1 • PTPRC • HLA-DQB1 • MECOM • NCAM1 • NUP214 • TCF3 • FUS • HLA-B • KAT6A • DEK • AFDN • EGR1 • MLLT10","pipe":" | ","alterations":" MLL rearrangement • NUP98 rearrangement","tags":["FLT3 • NPM1 • RUNX1 • KMT2A • ETV6 • CD38 • CREBBP • NUP98 • AFF1 • HLA-DRB1 • PTPRC • HLA-DQB1 • MECOM • NCAM1 • NUP214 • TCF3 • FUS • HLA-B • KAT6A • DEK • AFDN • EGR1 • MLLT10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • NUP98 rearrangement"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 11/03/2022","start_date":" 11/03/2022","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-03-11"},{"id":"d88c1ac7-6c49-4687-9631-89d59339a7df","acronym":"","url":"https://clinicaltrials.gov/study/NCT04990323","created_at":"2021-08-04T13:53:03.286Z","updated_at":"2024-07-02T16:35:18.901Z","phase":"Phase 1/2","brief_title":"US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies","source_id_and_acronym":"NCT04990323","lead_sponsor":"ExCellThera inc.","biomarkers":" HLA-DRB1 • CD34","pipe":"","alterations":" ","tags":["HLA-DRB1 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • clofarabine • fludarabine IV • thiotepa • busulfan • Zemcelpro (dorocubicel) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-02-19"},{"id":"71fc721d-5bad-462d-8429-6b4666cc5367","acronym":"","url":"https://clinicaltrials.gov/study/NCT04024761","created_at":"2021-01-18T19:45:31.523Z","updated_at":"2024-07-02T16:35:20.644Z","phase":"Phase 1","brief_title":"A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT04024761","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CIML NK • cyclophosphamide intravenous"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 50","initiation":"Initiation: 08/31/2019","start_date":" 08/31/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-06"},{"id":"7b20d6d4-1189-47d1-bd64-55eb31d095f7","acronym":"HAP2HCT","url":"https://clinicaltrials.gov/study/NCT03849651","created_at":"2021-01-18T19:00:01.850Z","updated_at":"2024-07-02T16:35:22.870Z","phase":"Phase 2","brief_title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","source_id_and_acronym":"NCT03849651 - HAP2HCT","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" FLT3 • RUNX1 • KMT2A • ETV6 • WT1 • CREBBP • NUP98 • NSD1 • HOXA9 • NUP214 • CBFA2T3 • GLIS2 • KAT6A • KDM5A • DEK • AFDN • MLLT10","pipe":" | ","alterations":" FLT3-ITD mutation • WT1 mutation • MLL fusion • NUP98-NSD1 fusion","tags":["FLT3 • RUNX1 • KMT2A • ETV6 • WT1 • CREBBP • NUP98 • NSD1 • HOXA9 • NUP214 • CBFA2T3 • GLIS2 • KAT6A • KDM5A • DEK • AFDN • MLLT10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • WT1 mutation • MLL fusion • NUP98-NSD1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Blincyto (blinatumomab) • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 01/31/2019","start_date":" 01/31/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-01-19"},{"id":"49acb1b2-8040-40ee-8448-aedf59cc118d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05009719","created_at":"2021-08-17T13:53:09.392Z","updated_at":"2024-07-02T16:35:24.505Z","phase":"Phase 1/2","brief_title":"Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy","source_id_and_acronym":"NCT05009719","lead_sponsor":"St. Petersburg State Pavlov Medical University","biomarkers":" TP53 • FLT3 • KMT2A • NUP98","pipe":" | ","alterations":" TP53 mutation • MLL rearrangement","tags":["TP53 • FLT3 • KMT2A • NUP98"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • MLL rearrangement"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/01/2021","start_date":" 04/01/2021","primary_txt":" Primary completion: 04/01/2023","primary_completion_date":" 04/01/2023","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2024-01-04"},{"id":"a6aad9f1-0518-4d3b-a71b-32706868cb46","acronym":"ADVL1521","url":"https://clinicaltrials.gov/study/NCT03190915","created_at":"2021-01-18T15:44:00.418Z","updated_at":"2024-07-02T16:35:29.990Z","phase":"Phase 2","brief_title":"Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia","source_id_and_acronym":"NCT03190915 - ADVL1521","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1 • PTPN11","pipe":" | ","alterations":" NF1 mutation • RAS mutation • PTPN11 mutation • CBL mutation","tags":["NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation • RAS mutation • PTPN11 mutation • CBL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/09/2018","start_date":" 09/09/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-11-08"},{"id":"b101cbe7-4c17-4af5-80e0-48b3f43e803f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00167219","created_at":"2022-04-24T08:54:13.043Z","updated_at":"2024-07-02T16:35:30.071Z","phase":"Phase 1/2","brief_title":"Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)","source_id_and_acronym":"NCT00167219","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 11/18/1999","start_date":" 11/18/1999","primary_txt":" Primary completion: 07/12/2022","primary_completion_date":" 07/12/2022","study_txt":" Completion: 08/09/2023","study_completion_date":" 08/09/2023","last_update_posted":"2023-11-07"},{"id":"7768c77e-c7df-4a92-91ad-6751d0d3d024","acronym":"BMT CTN 0201","url":"https://clinicaltrials.gov/study/NCT00075816","created_at":"2021-01-18T00:12:11.695Z","updated_at":"2024-07-02T16:35:58.204Z","phase":"Phase 3","brief_title":"Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)","source_id_and_acronym":"NCT00075816 - BMT CTN 0201","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(5q)","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"],"overall_status":"Completed","enrollment":" Enrollment 551","initiation":"Initiation: 01/01/2004","start_date":" 01/01/2004","primary_txt":" Primary completion: 04/01/2013","primary_completion_date":" 04/01/2013","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2023-01-04"},{"id":"7acaf31c-df41-4b59-9766-7689b8426466","acronym":"","url":"https://clinicaltrials.gov/study/NCT00423514","created_at":"2021-01-18T01:29:23.216Z","updated_at":"2024-07-02T16:35:58.519Z","phase":"Phase 1/2","brief_title":"Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease","source_id_and_acronym":"NCT00423514","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clofarabine • melphalan • thiotepa • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 11/20/2006","start_date":" 11/20/2006","primary_txt":" Primary completion: 06/18/2021","primary_completion_date":" 06/18/2021","study_txt":" Completion: 06/18/2021","study_completion_date":" 06/18/2021","last_update_posted":"2022-12-26"},{"id":"d12d96b8-74ae-4497-a19e-62e5444280b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01384513","created_at":"2022-01-21T21:56:53.421Z","updated_at":"2024-07-02T16:36:00.226Z","phase":"Phase 2","brief_title":"A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies","source_id_and_acronym":"NCT01384513","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 08/04/2011","start_date":" 08/04/2011","primary_txt":" Primary completion: 11/13/2020","primary_completion_date":" 11/13/2020","study_txt":" Completion: 11/16/2022","study_completion_date":" 11/16/2022","last_update_posted":"2022-11-17"},{"id":"db9bc1cc-4fe3-49ba-87ca-2ae0ae8eda08","acronym":"PHINK","url":"https://clinicaltrials.gov/study/NCT05304754","created_at":"2022-03-31T17:52:54.253Z","updated_at":"2024-07-02T16:36:14.448Z","phase":"Phase 1/2","brief_title":"\"Phase I / II Study on Infusion of Natural Killer Cells After Haploidentical Transplantation in Pediatric Patients\"","source_id_and_acronym":"NCT05304754 - PHINK","lead_sponsor":"Instituto de Investigación Hospital Universitario La Paz","biomarkers":" IL15","pipe":"","alterations":" ","tags":["IL15"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/30/2020","start_date":" 11/30/2020","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 05/01/2023","study_completion_date":" 05/01/2023","last_update_posted":"2022-03-31"},{"id":"512399c8-a561-4a89-832d-8df71551b9f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02120157","created_at":"2021-01-18T09:48:59.899Z","updated_at":"2024-07-02T16:36:20.177Z","phase":"Phase 2","brief_title":"Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies","source_id_and_acronym":"NCT02120157","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • busulfan • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 07/02/2015","start_date":" 07/02/2015","primary_txt":" Primary completion: 06/15/2018","primary_completion_date":" 06/15/2018","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2021-11-26"},{"id":"59320b4f-78cf-4636-bc0f-1335041f19cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01020539","created_at":"2021-01-18T04:00:10.514Z","updated_at":"2024-07-02T16:36:26.842Z","phase":"Phase 1","brief_title":"Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia","source_id_and_acronym":"NCT01020539","lead_sponsor":"Columbia University","biomarkers":" FLT3 • CD33","pipe":" | ","alterations":" FLT3 mutation • CD33 positive","tags":["FLT3 • CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • fludarabine IV • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 09/11/2002","start_date":" 09/11/2002","primary_txt":" Primary completion: 07/20/2011","primary_completion_date":" 07/20/2011","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2021-08-06"},{"id":"7ef2e0f3-1263-4490-9b0d-ea0be571f605","acronym":"","url":"https://clinicaltrials.gov/study/NCT00489203","created_at":"2021-01-18T01:44:52.854Z","updated_at":"2025-02-25T16:22:35.314Z","phase":"Phase 2","brief_title":"Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","source_id_and_acronym":"NCT00489203","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 04/01/2007","start_date":" 04/01/2007","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":"","study_completion_date":"","last_update_posted":"2021-02-03"},{"id":"5063235e-ff35-4131-9838-661453788f13","acronym":"","url":"https://clinicaltrials.gov/study/NCT01445080","created_at":"2021-01-18T05:59:35.791Z","updated_at":"2025-02-25T16:23:43.042Z","phase":"Phase 1/2","brief_title":"Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia","source_id_and_acronym":"NCT01445080","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 05/30/2006","start_date":" 05/30/2006","primary_txt":" Primary completion: 03/16/2012","primary_completion_date":" 03/16/2012","study_txt":" Completion: 12/10/2012","study_completion_date":" 12/10/2012","last_update_posted":"2021-02-02"}]